Delivery and biodistribution of siRNA for cancer therapy: Challenges and future prospects

Therapeutic Delivery

Volumn 3, Issue 2, 2012, Pages 245-261

  Seth, Shaguna ^a   Johns, Rachel ^a   Templin, Michael V ^a  

^a Marina Biotech Inc   (United States)

Author keywords

Endogenous process that provides post transcriptional gene regulation by sequence specific downregulation of target mRNA with the use of siRNA

Indexed keywords

SMALL INTERFERING RNA;

CANCER GENE THERAPY; CANCER REGRESSION; CELL TRANSPORT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TRANSPORT; EWING SARCOMA; GENE DELIVERY SYSTEM; GENE SILENCING; HEPATITIS B; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; INTERNALIZATION; LIPOSOMAL DELIVERY; LIVER CANCER; NEUROBLASTOMA; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; RNA INTERFERENCE; RNA STABILITY; SIDE EFFECT; SINGLE DRUG DOSE; TOXICITY TESTING;

EID: 84857185112     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.155     Document Type: Review

References (135)

1. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101(1), 25-33 (2000).
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811 (1998). (Pubitemid 28099681)
3. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409(6818), 363-366 (2001). (Pubitemid 32151243)
4. Okamura K, Chung WJ, Ruby JG, Guo H, Bartel DP, Lai EC. The Drosophila hairpin RNA pathway generates endogenous short interfering RNAs. Nature 453(7196), 803-806 (2008). (Pubitemid 351793790)
5. Okamura K, Balla S, Martin R, Liu N, Lai EC. Two distinct mechanisms generate endogenous siRNAs from bidirectional transcription in Drosophila melanogaster. Nat. Struct. Mol. Biol. 15(6), 581-590 (2008). (Pubitemid 351799142)
6. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2- containing RNAi enzyme complexes. Cell 123(4), 607-620 (2005). (Pubitemid 41608464)
7. Chendrimada TP, Gregory RI, Kumaraswamy E et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436(7051), 740-744 (2005). (Pubitemid 41117280)
8. Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD. A protein sensor for siRNA asymmetry. Science 306(5700), 1377-1380 (2004). (Pubitemid 39532515)
9. Ameres SL, Martinez J, Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130(1), 101-112 (2007). (Pubitemid 47031315)
10. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl Acad. Sci. USA 101(40), 14385-14389 (2004). (Pubitemid 39346758)
11. Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv. Drug Deliv. Rev. 60(4-5), 530-536 (2008).
12. de FA, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6(6), 443-453 (2007). (Pubitemid 47064567)
13. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA 10(5), 766-771 (2004). (Pubitemid 38529739)
14. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2(12), 711-719 (2006). (Pubitemid 44764213)
15. Braasch DA, Paroo Z, Constantinescu A et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14(5), 1139-1143 (2004). (Pubitemid 38229843)
16. Bramsen JB , Kjems J. Chemical modification of small interfering RNA. Methods Mol. Biol. 721, 77-103 (2011).
17. Chiu YL , Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 9(9), 1034-1048 (2003). (Pubitemid 37093614)
18. Gao S, Dagnaes-Hansen F, Nielsen EJ et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17(7), 1225-1233 (2009).
19. Laursen MB, Pakula MM, Gao S et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. Biosyst. 6(5), 862-870 (2010).
20. Jackson AL, Burchard J, Leake D et al. Position-specific chemical modification of siRNAs reduces 'off-target' transcript silencing. RNA 12(7), 1197-1205 (2006). (Pubitemid 43990545)
21. Kenski DM, Cooper AJ, Li JJ et al. Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res. 38(2), 660-671 (2010).
22. Vaish N, Chen F, Seth S et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 39(5), 1823-1832 (2011).
23. Ui-Tei K, Naito Y, Nishi K, Juni A, Saigo K. Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res. 36(22), 7100-7109 (2008).
24. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23(4), 457-462 (2005). (Pubitemid 41724921)
25. Sioud M. Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA interference. Methods Mol. Biol. 629, 33-52 (2010).
26. Kato H, Takahasi K, Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol. Rev. 243(1), 91-98 (2011).
27. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4), 778-809 (2001). (Pubitemid 32979631)
28. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 and TLR8. Handb. Exp. Pharmacol. 183, 71-86 (2008).
29. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172(11), 6545-6549 (2004). (Pubitemid 38669088)
30. Sioud M. Recent advances in small interfering RNA sensing by the immune system. Nat. Biotechnol. 27(3), 236-242 (2010).
31. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 19(2), 89-102 (2009).
32. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13(3), 494-505 (2006). (Pubitemid 43257617)
33. Abrams MT, Koser ML, Seitzer J et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol. Ther. 18(1), 171-180 (2010).
34. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm. Res. 20(9), 1337-1350 (2003). (Pubitemid 37164040)
35. Mosser DM , Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8(12), 958-969 (2008).
36. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505-515 (2008).
37. Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 6(3), 686-695 (2009).
38. Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24(3), 438-449 (2007). (Pubitemid 46295166)
39. van Lookeren CM, Wiesmann C, Brown EJ. Macrophage complement receptors and pathogen clearance. Cell Microbiol. 9(9), 2095-2102 (2007). (Pubitemid 47250283)
40. Scherphof GL , Kamps JA. The role of hepatocytes in the clearance of liposomes from the blood circulation. Prog. Lipid Res. 40(3), 149-166 (2001). (Pubitemid 32220186)
41. Litzinger DC, Buiting AM, van RN, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1190(1), 99-107 (1994). (Pubitemid 24066264)
42. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12(4), 492-503 (2010).
43. Woodle MC, Newman MS, Cohen JA. Sterically stabilized liposomes: physical and biological properties. J. Drug Target. 2(5), 397-403 (1994).
44. Campbell NE, Kellenberger L, Greenaway J, Moorehead RA, Linnerth-Petrik NM, Petrik J. Extracellular matrix proteins and tumor angiogenesis. J. Oncol. 2010, 586905 (2010).
45. Jain RK. Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin. Cancer Res. 5(7), 1605-1606 (1999). (Pubitemid 29334434)
46. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 18(6), 884-901 (2010).
47. Gerlowski LE , Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31(3), 288-305 (1986). (Pubitemid 16076428)
48. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271-284 (2000). (Pubitemid 30122932)
49. Au JL, Jang SH, Zheng J et al. Determinants of drug delivery and transport to solid tumors. J. Control. Release 74(1-3), 31-46 (2001). (Pubitemid 32727607)
50. Jain RK , Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
51. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 67(22), 10664-10668 (2007). (Pubitemid 350145891)
52. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60(9), 2497-2503 (2000). (Pubitemid 30262444)
53. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol. Rev. 77(3), 759-803 (1997).
54. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 61(9), 721-731 (2009).
55. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8(15), 1188-1196 (2001). (Pubitemid 32776393)
56. Hafez IM , Cullis PR. Roles of lipid polymorphism in intracellular delivery. Adv. Drug Deliv. Rev. 47(2-3), 139-148 (2001). (Pubitemid 32324111)
57. David S, Pitard B, Benoit JP, Passirani C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 62(2), 100-114 (2010).
58. El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 11(1), 13-22 (2009).
59. Hitz T, Iten R, Gardiner J, Namoto K, Walde P, Seebach D. Interaction of alpha-and beta-oligoarginine-acids and amides with anionic lipid vesicles: a mechanistic and thermodynamic study. Biochemistry 45(18), 5817-5829 (2006).
60. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10(3), 310-315 (2004). (Pubitemid 38667624)
61. Yang ST, Zaitseva E, Chernomordik LV, Melikov K. Cell-penetrating peptide induces leaky fusion of liposomes containing late endosome-specific anionic lipid. Biophys. J. 99(8), 2525-2533 (2010).
62. Oh YK , Park TG. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61(10), 850-862 (2009).
63. Li J, Huang L. Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond.) 5(10), 1483-1486 (2010).
64. Li SD, Huang L. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr. Opin. Invest. Drugs 9(12), 1317-1323 (2008).
65. Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J. 11(4), 639-652 (2009).
66. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22(3), 362-372 (2005). (Pubitemid 40558494)
67. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23(8), 1002-1007 (2005). (Pubitemid 41114035)
68. Zimmermann TS, Lee AC, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111-114 (2006).
69. Judge AD, Robbins M, Tavakoli I et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119(3), 661-673 (2009).
70. Geisbert TW, Hensley LE, Kagan E et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193(12), 1650-1657 (2006). (Pubitemid 43839469)
71. Akinc A, Zumbuehl A, Goldberg M et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26(5), 561-569 (2008). (Pubitemid 351668042)
72. Akinc A, Goldberg M, Qin J et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17(5), 872-879 (2009).
73. Love KT, Mahon KP, Levins CG et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107(5), 1864-1869 (2010).
74. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010).
75. Cullis PR, de KB, Verkleij AJ, Hope MJ. Lipid polymorphism and membrane fusion. Biochem. Soc. Trans. 14(2), 242-245 (1986).
76. Gao X , Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 35(3), 1027-1036 (1996). (Pubitemid 26034590)
77. Li SD , Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann. NY Acad. Sci. 1082, 1-8 (2006). (Pubitemid 44955442)
78. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16(5), 942-946 (2008). (Pubitemid 351587105)
79. Chono S, Li SD, Conwell CC, Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Control. Release 131(1), 64-69 (2008).
80. Li SD , Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release 145(3), 178-181 (2010).
81. Santel A, Aleku M, Keil O et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13(18), 1360-1370 (2006). (Pubitemid 44323692)
82. Adami RC, Seth S, Harvie P et al. An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol. Ther. 19(6), 1141-1151 (2011).
83. Nakase I, Niwa M, Takeuchi T et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10(6), 1011-1022 (2004). (Pubitemid 39625245)
84. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL, Wender PA. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J. Med. Chem. 45(17), 3612-3618 (2002). (Pubitemid 34856101)
85. Seth S, Matsui Y, Fosnaugh K et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol. Ther. 19(5), 928-935 (2011).
86. Andreakos E, Rauchhaus U, Stavropoulos A et al. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum. 60(4), 994-1005 (2009).
87. Li S, Huang L. Functional polymorphism of liposomal gene delivery vectors: lipoplex and lipopolyplex. In: Liposomes: Rational Design. Janoff A (Ed.), Marcel Dekker, NY, USA 89-124 (1999).
88. Landen CN, Merritt WM, Mangala LS et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol. Ther. 5(12), 1708-1713 (2006).
89. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104(39), 15549-15554 (2007). (Pubitemid 47502954)
90. Ali MM, Yoo B, Pagel MD. Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol. Pharm. 6(5), 1409-1416 (2009).
91. Shi B, Keough E, Matter A et al. Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J. Histochem. Cytochem. 59(8), 727-740 (2011).
92. Pei Y, Hancock PJ, Zhang H et al. Quantitative evaluation of siRNA delivery in vivo. RNA 16(12), 2553-2563 (2010).
93. Gunther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur. J. Pharm. Biopharm. 77(3), 438-449 (2011).
94. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116(2), 123-129 (2006). (Pubitemid 44854271)
95. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129(2), 107-116 (2008).
96. Liu X, Huang H, Wang J et al. Dendrimersdelivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem. Pharmacol. 82(1), 17-23 (2011).
97. Wakefield DH, Klein JJ, Wolff JA, Rozema DB. Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size. Bioconjug. Chem. 16(5), 1204-1208 (2005). (Pubitemid 41368122)
98. Rozema DB, Lewis DL, Wakefield DH et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104(32), 12982-12987 (2007). (Pubitemid 351737577)
99. Albarran B, Hoffman AS, Stayton PS. Efficient intracellular delivery of a proapoptotic peptide with a pH-responsive carrier. React. Funct. Polym. 71(3), 261-265 (2011).
100. Convertine AJ, Diab C, Prieve M et al. pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules 11(11), 2904-2911(2010).
101. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65(19), 8984-8992 (2005). (Pubitemid 41377390)
102. Heidel JD, Yu Z, Liu JY et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104(14), 5715-5721 (2007). (Pubitemid 47175600)
103. Watanabe K, Harada-Shiba M, Suzuki A et al. In vivo siRNA delivery with dendritic poly(l-lysine) for the treatment of hypercholesterolemia. Mol. Biosyst. 5(11), 1306-1310 (2009).
104. Chou ST, Leng Q, Scaria P, Woodle M, Mixson AJ. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo. Cancer Gene Ther. 18(10), 707-716 (2011).
105. Eguchi A, Dowdy SF. siRNA delivery using peptide transduction domains. Trends Pharmacol. Sci. 30(7), 341-345 (2009).
106. Akita H, Kogure K, Moriguchi R et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J. Control. Release 143(3), 311-317 (2010).
107. Kim SW, Kim NY, Choi YB, Park SH, Yang JM, Shin S. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J. Control. Release 143(3), 335-343 (2010).
108. Tanaka K, Kanazawa T, Shibata Y et al. Development of cell-penetrating peptidemodified MPEG-PCL diblock copolymeric nanoparticles for systemic gene delivery. Int. J. Pharm. 396(1-2), 229-238 (2010).
109. Wang M , Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 62(2), 90-99 (2010).
110. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J. Control. Release 151(2), 149-154 (2011).
111. Nie Y, Gunther M, Gu Z, Wagner E. Pyridylhydrazone-based PEGylation for pH-reversible lipopolyplex shielding. Biomaterials 32(3), 858-869 (2011).
112. Shin J, Shum P, Thompson DH. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control. Release 91(1-2), 187-200 (2003). (Pubitemid 37288890)
113. Hatakeyama H, Akita H, Ito E et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 32(18), 4306-4316 (2011).
114. Ishida O, Maruyama K, Tanahashi H et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18(7), 1042-1048 (2001). (Pubitemid 32799953)
115. Laginha KM, Moase EH, Yu N, Huang A, Allen TM. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2- overexpressing breast cancer. J. Drug Target. 16(7), 605-610 (2008).
116. Park JW, Hong K, Kirpotin DB et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8(4), 1172-1181 (2002). (Pubitemid 35177372)
117. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319(5863), 627-630 (2008). (Pubitemid 351197066)
118. Peer D, Shimaoka M. Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle 8(6), 853-859 (2009).
119. Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 18(2), 456-468 (2007). (Pubitemid 46493517)
120. Bartlett DW, Davis ME. Impact of tumorspecific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99(4), 975-985 (2008). (Pubitemid 351316639)
121. Adams GP, Schier R, McCall AM et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77(9), 1405-1412 (1998). (Pubitemid 28190739)
122. Elbayoumi TA, Pabba S, Roby A, Torchilin VP. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 17(1), 1-14 (2007). (Pubitemid 46631140)
123. Kamaly N, Kalber T, Thanou M, Bell JD, Miller AD. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug. Chem. 20(4), 648-655 (2009).
124. Leimgruber A, Berger C, Cortez-Retamozo V et al. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia 11(5), 459-468, 2 (2009).
125. Turk MJ, Waters DJ, Low PS. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213(2), 165-172 (2004). (Pubitemid 39140974)
126. Thomas M, Kularatne SA, Qi L et al. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci. 1175, 32-39 (2009).
127. Zhao XB , Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug Deliv. Rev. 56(8), 1193-1204 (2004). (Pubitemid 38496515)
128. Reddy JA , Low PS. Enhanced folate receptor mediated gene therapy using a novel pHsensitive lipid formulation. J. Control. Release 64(1-3), 27-37 (2000). (Pubitemid 30035305)
129. Yu B, Zhao X, Lee LJ, Lee RJ. Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 11(1), 195-203 (2009).
130. Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32(19), e149 (2004).
131. Schiffelers RM , Storm G. ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opin. Drug Deliv. 3(3), 445-454 (2006). (Pubitemid 43772718)
132. Pirollo KF, Zon G, Rait A et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17(1), 117-124 (2006). (Pubitemid 43100520)
133. Pirollo KF, Rait A, Zhou Q et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67(7), 2938-2943 (2007). (Pubitemid 46724828)
134. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6(9), 1130-1146 (2011).
135. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).